Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)

被引:1
|
作者
Cegledi, Andrea [1 ]
Csukly, Zoltan [1 ]
Fekete, Monika [2 ]
Kozma, Andras [3 ]
Szemlaky, Zsuzsanna [1 ]
Andrikovics, Hajnalka [3 ]
Mikala, Gabor [1 ]
机构
[1] Cent Hosp Southern Pest, Natl Inst Hematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, Budapest, Hungary
[2] Semmelweis Univ, Dept Publ Hlth, Budapest, Hungary
[3] Cent Hosp Southern Pest, Natl Inst Hematol & Infect Dis, Lab Mol Genet, Budapest, Hungary
关键词
multiple myeloma; venetoclax; translocation t(6; 14); IGH::CCND3; personalized therapy; HIGH-RISK MYELOMA; EXPRESSION; THERAPY; DEXAMETHASONE; COMBINATION; BORTEZOMIB; EFFICACY; MODEL;
D O I
10.3389/pore.2023.1611375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) IGH::CCND3 translocation remains less investigated.Methods: In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes.Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and alkylator treatment refractory patient, achieved sustained stringent complete remission (sCR) after combining carfilzomib-dexamethasone with venetoclax, which was his best response ever. Similarly, Patient 2, refractory to frontline bortezomib-thalidomide-dexamethasone therapy, attained CR following a transition to bortezomib-dexamethason-venetoclax treatment. Patient 3, who was immunomodulatory (IMID)-intolerant, showed a highly favorable response to venetoclax-dexamethasone therapy after his first relapse following autologous stem cell transplantation. No significant adverse effects were observed in any of the patients.Discussion: Our study provides compelling preliminary evidence for the efficacy of venetoclax in t(6;14) translocation-associated myeloma. The outcomes observed in our patients suggest that venetoclax-based therapy holds substantial promise as an effective treatment option for this specific genetic subgroup. Furthermore, the similarities in treatment response between t(11;14) and t(6;14) translocation subgroups highlight the importance of personalized approaches targeting specific genetic abnormalities to optimize therapeutic outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Combination Venetoclax and Selinexor Effective in Relapsed/Refractory Multiple Myeloma with Translocation t(11;14)
    Nguyen, Nina
    Chaudhry, Sana
    Totiger, Tulasigeri M.
    Montoya, Skye
    Afaghani, Jumana
    Bradley, Terrence
    Maura, Francesco
    Kazandjian, Dickran
    Chapman, Jennifer R.
    Landgren, Ola
    Hoffman, James E.
    Taylor, Justin
    BLOOD, 2021, 138
  • [2] Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
    Nguyen, Nina
    Chaudhry, Sana
    Totiger, Tulasigeri M.
    Diaz, Robert
    Roberts, Evan
    Montoya, Skye
    Pardo, Gabriel
    Pardo, Alejandro
    Afaghani, Jumana
    Affer, Maurizio
    Jahn, Jacob
    Bradley, Terrence
    Maura, Francesco
    Kazandjian, Dickran
    Bilbao, Daniel
    Chapman, Jennifer
    Landgren, Ola
    Hoffman, James
    Taylor, Justin
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [3] Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
    Chaudhry, Sana
    Nguyen, Nina
    Khurana, Rimpi
    Totiger, Tulasigeri M.
    Montoya, Skye
    Afaghani, Jumana
    Bradley, Terrence
    Maura, Francesco
    Kazandjian, Dickran
    Chapman, Jennifer
    Schurer, Stephan
    Landgren, Ola
    Hoffman, James
    Taylor, Justin
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
    Nina Nguyen
    Sana Chaudhry
    Tulasigeri M. Totiger
    Robert Diaz
    Evan Roberts
    Skye Montoya
    Gabriel Pardo
    Alejandro Pardo
    Jumana Afaghani
    Maurizio Affer
    Jacob Jahn
    Terrence Bradley
    Francesco Maura
    Dickran Kazandjian
    Daniel Bilbao
    Jennifer Chapman
    Ola Landgren
    James Hoffman
    Justin Taylor
    npj Precision Oncology, 6
  • [5] Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma
    Dima, Danai
    Orland, Mark
    Ullah, Fauzia
    Anwer, Faiz
    Mazzoni, Sandra
    Raza, Shahzad
    Chaulagain, Chakra P.
    Samaras, Christy
    Valent, Jason
    Williams, Louis
    Khouri, Jack
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11): : 857 - 860
  • [6] Detection and monitoring of t(11;14) in liquid biopsies from patients with relapsed/refractory multiple myeloma treated with venetoclax-based regimens
    Li, Xiaotong
    Saal, Lao H.
    Brueffer, Christian
    Chen, Yilun
    Asklin, Johanna
    Alvi, Saman
    Venkatram, Srinivas
    Ross, Jeremy A.
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma
    Basali, Diana
    Chakraborty, Rajshekhar
    Rybicki, Lisa
    Rosko, Nathaniel
    Reed, Janice
    Karam, Mary Ann
    Schlueter, Kristen
    Dysert, Hayley
    Faiman, Beth M.
    Hamilton, Kimberly
    Kalaycio, Matt
    Valent, Jason
    BLOOD, 2019, 134
  • [8] Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma
    Basali, Diana
    Chakraborty, Rajshekhar
    Rybicki, Lisa
    Rosko, Nathaniel
    Reed, Janice
    Karam, Maryann
    Schlueter, Kristen
    Dysert, Hayley
    Kalaycio, Matt
    Valent, Jason
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (06) : 1136 - 1140
  • [9] A Single-Center Experience on the Safety and Efficacy of Venetoclax-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma
    Zolotov, Eli
    Patel, Vanisha
    Weiss, Yedidyah
    Biran, Noa
    Phull, Pooja
    Vesole, David H.
    Siegel, David S.
    Parmar, Harsh
    BLOOD, 2024, 144 : 6959 - 6960
  • [10] Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
    Ehsan, Hamid
    Wahab, Ahsan
    Shah, Zunairah
    Sana, Muhammad Khawar
    Masood, Adeel
    Rafae, Abdul
    Hashmi, Hamza
    JOURNAL OF HEMATOLOGY, 2021, 10 (03) : 89 - 97